Dmitry Balyasny’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-4,500
Closed -$822K – 2887
2025
Q4
$822K Sell
4,500
-2,000
-31% -$279K ﹤0.01% 2282
2025
Q3
$789K Buy
6,500
+1,400
+27% +$158K ﹤0.01% 2216
2025
Q2
$532K Sell
5,100
-1,800
-26% -$191K ﹤0.01% 2272
2025
Q1
$805K Buy
+6,900
New +$786K ﹤0.01% 2086
2024
Q4
– Sell
-4,700
Closed -$422K – 2725
2024
Q3
$422K Buy
+4,700
New +$410K ﹤0.01% 2333
2023
Q3
– Sell
-39,000
Closed -$2.8M – 2251
2023
Q2
$2.8M Buy
+39,000
New +$2.88M 0.01% 1261
2020
Q4
– Sell
-40,000
Closed -$2.85M – 1319
2020
Q3
$2.85M Buy
+40,000
New +$3.12M 0.02% 745

Other funds holding AXSM

Dmitry Balyasny's AXSM Position: Q3 2026 in Review

Dmitry Balyasny sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 76,250 shares — an estimated $18.7M sold.

Dmitry Balyasny first reported a position in AXSM in Q1 2018 and held it in 9 quarters. The position peaked at $18.7M in Q2 2026. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Dmitry Balyasny reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 76,250 Axsome Therapeutics shares in Q3 2026, an estimated $18.7M.
  • Dmitry Balyasny first reported a position in Axsome Therapeutics in Q1 2018 and held it in 9 quarters.
  • Dmitry Balyasny's Axsome Therapeutics position peaked at $18.7M in Q2 2026.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.